IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or “the Company”) (NASDAQ: IMMX) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immix announced the termination of Chief Medical Officer Richard Graydon on July 20, 2026, for “reasons unrelated to his activities at the company.” According to media reports, Graydon was actually Ronald L. Fischer, who disappeared during a 2005 rape trial and lived as a fugitive for 20 years before his arrest in July 2026. Based on this news, shares of Immix fell by more than 14.1%.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com
